Learning Objectives:

At the conclusion of the educational presentation, the participant will be able to:

• • Discuss AE management, patient/care partner education, therapy sequencing, and bridging therapy for the latest treatments for patients with multiple myeloma, including upfront quadruplet regimens, T-cell engagers (bispecific antibodies), CAR-T cell therapy, CD-38 antibodies, SINE inhibitors, CELMoDs, and antibody-drug conjugates
    
  • Use tactics to enhance access to therapies and clinical trials, including best practices for transitions of care
    
  • Explain the importance of minimal residual disease (MRD) and identify treatment strategies to attain it
    
  • Identify disparities faced by patients with multiple myeloma and summarize strategies to overcome these, including increasing participation in clinical trials (eg, health equity)​